Sun Pharmaceutical Industries Limited

BSE: 524715 NSE: SUNPHARMA
Sun Pharmaceutical Industries Limited - pharma in Vadodara, Gujarat, India. FY 2026 financials and compliance.
CIN L24230GJ1993PLC019050 Incorporated 01 March 1993 ROC Ahmedabad HQ Vadodara, Gujarat, India
Active Listed - NSE: SUNPHARMA · BSE: 524715 Public Limited Company pharma
Data last updated
Revenue · FY 2026
₹58,462 Cr
▲ 11.19% YoY
EBITDA · FY 2026
₹19,703 Cr
▲ 14.31% YoY
Net profit · FY 2026
₹11,509 Cr
▲ 4.96% YoY
Authorised capital
₹600 Cr
Registered with MCA
Paid-up capital
₹239.93 Cr
Issued & subscribed
Open charges
₹16.06 Cr
Satisfied ₹1,785.22 Cr
Company age
33 yrs
Est. 1993
Employees · EPFO
16,436
Latest available

About Sun Pharmaceutical Industries Limited

Data last updated: 18 December 2025

Sun Pharmaceutical Industries Limited is a public limited company based in Vadodara, Gujarat, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 01 March 1993, the company has been in operation for over 33 years.

Registered with ROC Ahmedabad under CIN L24230GJ1993PLC019050. Listed on BSE: 524715 and NSE: SUNPHARMA.

Capital: an authorised share capital of ₹600 Cr and a paid-up capital of ₹239.93 Cr. It is led by directors including Dilip Shantilal Shanghvi and Pawan Kumar Goenka.

Last AGM: 31 July 2025. Financial statements filed for year ended 31 March 2025. Office: Sparc Tandalja, Vadodara, Gujarat, India – 390012.

As per the financials filed for FY 2025, the company reported a revenue of ₹54,543 Cr, a growth of 9% compared to the previous year.

The company has a workforce of approximately 16,436 employees as per the latest available data. Its group structure includes 14 subsidiaries.

The company is associated with 2 brands - Flore, Sun Pharma. As per MCA filings, the company has open charges of ₹16.06 Cr and satisfied charges of ₹1,785.22 Cr on record.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sunpharma.com.

Company Details of Sun Pharmaceutical Industries Limited
CIN L24230GJ1993PLC019050
Registration Number 019050
Incorporation Date 01 March 1993
ROC Ahmedabad
Listing Status Listed (BSE: 524715, NSE: SUNPHARMA)
Company Status Active
Date of Last AGM 31 July 2025
Date of Balance Sheet 31 March 2025
Compliance Status Active Compliant
Key People
Kirti Wardhaman Ganorkar Managing Director Dilip Shantilal Shanghvi Whole-Time Director Aalok Dilip Shanghvi Whole-Time Director
Contact Details
  • Email
    *****@*****.com
  • Telephone
    +91-****-******
  • Website
    sunpharma.com
  • Social Media
  • Registered Address
    Sparc Tandalja, Vadodara, Gujarat, India – 390012
  • Industry
    Pharma, Drug Formulation & Development, API Manufacturers
Company report
Sun Pharmaceutical Industries Limited - full intelligence report
  • Historical Financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Litigation, compliance and MCA filings
  • PDF report delivered after checkout
₹799 ₹999 20% off
Secure checkout · GST invoice included

Unlock the full Sun Pharmaceutical Industries Limited report

Financials, compliance, directors, charges, ownership and filings for Sun Pharmaceutical Industries Limited in one report.

10-year financials Directors & ownership Charges & compliance

Associated Brands with Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited operates two associated brands: Flore and Sun Pharma. These brands represent Sun Pharmaceutical Industries Limited's diversified market presence and brand portfolio.

Brand Description Website
Flore
Customized probiotics for gut health are provided via stool analysis. flore.com
Sun Pharma
Specialty generic pharmaceuticals and APIs are manufactured and marketed. sunpharma.com

Competitors & Alternatives of Sun Pharmaceutical Industries Limited

Brands and companies operating in the same space as Sun Pharmaceutical Industries Limited include Viome, Evvy, Elo Health and 6 more.

Competitor Description Location Founded
Viome Viome Machine learning-based bioinformatics solutions for health insights are provided. Los Alamos, United States, United States 2016
Evvy Evvy Vaginal microbiome test kits are provided through an online platform. New York, United States, United States 2002
Elo Health Elo Health Personalized supplements are delivered based on biochemical analysis. San Francisco, United States, United States 2020
Rootine Rootine Provider of personalized nutrition supplements Nashville, United States, United States 2018
Ombre Ombre Microbiome-based personalized supplements are offered via gut testing kits. San Francisco, United States, United States 2016
iSplack iSplack Athlete-focused body care products are manufactured with science-backed formulations. Boulder, United States, United States 2014
Jona Jona AI-powered microbiome profiling platform to improve digestive health Hialeah, United States, United States 2022
Wellnicity Wellnicity Personalized diet and supplement recommendations are provided via genetic analysis. Austin, United States, United States 2002
uBiome uBiome Provides comprehensive sequence datasets for human microbiome research and analysis. San Francisco, United States, United States 2012

Business Activity of Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited is engaged in the principal business activity of manufacturing, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group Code Description of Main Activity Business Activity Code Description of Business Activity Turnover Percentage
C Manufacturing C6 Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products *********

Auditor Details of Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited is audited by S R B C & CO LLP (ICAI peer reviewed, certificate valid till 2029-02-28) for the financial year 2026, as reported in its NSE exchange filings. The statutory auditor is responsible for expressing an independent opinion on whether the financial statements present a true and fair view in accordance with applicable accounting standards.

Name Financial year Audit opinion
S R B C & CO LLP (ICAI peer reviewed, certificate valid till 2029-02-28) FY 2026 Declaration of unmodified opinion

Board of Directors of Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited is currently managed by 13 directors, with 23 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.

Current Directors
Name Designation Appointment Date Tenure Status
Dilip Shantilal Shanghvi
Also directs: Sun Pharma Advanced Research Company Limited, Sun Petrochemicals Private Limited, Alfa Infraprop Private Limited and 3 more
Whole-Time Director 01 Apr 2008 18 Years 3 Months Current
Pawan Kumar Goenka
Also directs: Pmg Advisory Llp, Bosch Limited
Director 21 May 2021 5 Years 1 Months Current
Anoop Anjanikumar Deshpande Nodal Officer 05 Feb 2022 4 Years 5 Months Current
Meetal Sharad Sampat
Also directs: Sun Pharma Laboratories Limited, Realstone Infra Limited
Deputy Nodal Officer 11 Sep 2019 6 Years 10 Months Current
Kirti Wardhaman Ganorkar
Also directs: Sun Pharma Distributors Limited, Sun Pharma Laboratories Limited
Managing Director 01 Sep 2025 0 Years 10 Months Current
Rama Bijapurkar
Also directs: Gokaldas Exports Limited, Vst Industries Limited, Apollo Hospitals Enterprise Limited and 1 more
Director 21 May 2021 5 Years 1 Months Current
Showing 6 of 13 current directors. View all directors

Financials of Sun Pharmaceutical Industries Limited FY 2026 filings available

Sun Pharmaceutical Industries Limited reported revenue of ₹58,462 Cr (up 11.19% YoY) for FY 2026. Profit growth despite declining revenue indicates effective cost management and margin discipline.

Revenue · FY 2026
₹58,462 Cr ▲ 11.19%
Profit · FY 2026
₹11,509 Cr ▲ 4.96%
EBITDA · FY 2026
₹19,703 Cr ▲ 14.31%
Revenue₹ Cr · Consolidated020,00040,00060,000FY 2020: ₹32,838 Cr32,838FY 2020FY 2022: ₹38,654 Cr · +17.7% YoY38,654+17.7%FY 2022FY 2023: ₹43,886 Cr · +13.5% YoY43,886+13.5%FY 2023FY 2024: ₹48,497 Cr · +10.5% YoY48,497+10.5%FY 2024FY 2025: ₹52,578 Cr · +8.4% YoY52,578+8.4%FY 2025FY 2026: ₹58,462 Cr · +11.2% YoY58,462+11.2%FY 2026
Net Profit₹ Cr · Consolidated05,00010,00015,000FY 2020: ₹4,172 Cr4,172FY 2020FY 2022: ₹3,389 Cr · -18.8% YoY3,389-18.8%FY 2022FY 2023: ₹8,513 Cr · +151.2% YoY8,513+151.2%FY 2023FY 2024: ₹9,610 Cr · +12.9% YoY9,610+12.9%FY 2024FY 2025: ₹10,965 Cr · +14.1% YoY10,965+14.1%FY 2025FY 2026: ₹11,509 Cr · +5% YoY11,509+5%FY 2026
Quarterly Revenue₹ Cr · vs same quarter last year010,00020,000Q1'25: ₹12,653 Cr · +6% YoY12,653+6%Q1'25Q2'25: ₹13,291 Cr · +9% YoY13,291+9%Q2'25Q3'25: ₹13,675 Cr · +10.5% YoY13,675+10.5%Q3'25Q4'25: ₹12,959 Cr · +8.1% YoY12,959+8.1%Q4'25Q1'26: ₹13,851 Cr · +9.5% YoY13,851+9.5%Q1'26Q2'26: ₹14,478 Cr · +8.9% YoY14,478+8.9%Q2'26Q3'26: ₹15,521 Cr · +13.5% YoY15,521+13.5%Q3'26Q4'26: ₹14,612 Cr · +12.8% YoY14,612+12.8%Q4'26
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2020
Revenue from Operations ₹58,462 Cr ₹52,578 Cr ₹48,497 Cr ₹43,886 Cr ₹38,654 Cr ₹32,838 Cr
Other Income ₹1,971.72 Cr ₹1,965.04 Cr ₹1,354.19 Cr ₹634.52 Cr ₹921.51 Cr ₹635.98 Cr
Total Income ₹60,434 Cr ₹54,543 Cr ₹49,851 Cr ₹44,520 Cr ₹39,576 Cr ₹33,473 Cr
Cost of Materials Consumed ₹7,389.02 Cr ₹6,449.1 Cr ₹6,904.33 Cr ₹7,777.57 Cr ₹7,049.12 Cr ₹5,515.23 Cr
Purchases of Stock-in-Trade ₹3,811.53 Cr ₹4,147.95 Cr ₹3,466.15 Cr ₹3,571.5 Cr ₹3,410.03 Cr ₹3,414.37 Cr
Changes in Inventories ₹343.13 Cr ₹150.31 Cr ₹292.13 Cr -₹686.91 Cr -₹107.61 Cr ₹300.85 Cr
Employee Benefit Expense ₹11,419 Cr ₹9,973.12 Cr ₹9,429.06 Cr ₹8,296.03 Cr ₹7,300.83 Cr ₹6,362.35 Cr
Finance Costs ₹338.91 Cr ₹231.36 Cr ₹238.47 Cr ₹172 Cr ₹127.35 Cr ₹302.73 Cr
Depreciation & Amortisation ₹2,937.85 Cr ₹2,575.39 Cr ₹2,556.64 Cr ₹2,529.43 Cr ₹2,143.74 Cr ₹2,052.78 Cr
Other Expenses ₹17,768 Cr ₹16,586 Cr ₹15,382 Cr ₹13,281 Cr ₹10,604 Cr ₹10,255 Cr
Total Expenses ₹44,007 Cr ₹40,114 Cr ₹38,269 Cr ₹34,940 Cr ₹30,528 Cr ₹28,203 Cr
Profit Before Exceptional Items & Tax ₹16,426 Cr ₹14,430 Cr ₹11,582 Cr ₹9,579.88 Cr ₹9,048.14 Cr ₹5,270.23 Cr
Exceptional Items -₹1,307.48 Cr -₹677.85 Cr -₹494.32 Cr -₹171.45 Cr -₹4,566.82 Cr -₹260.64 Cr
Profit Before Tax ₹15,119 Cr ₹13,752 Cr ₹11,088 Cr ₹9,408.43 Cr ₹4,481.32 Cr ₹5,009.59 Cr
Total Tax Expense ₹3,554.36 Cr ₹2,772.03 Cr ₹1,439.45 Cr ₹847.59 Cr ₹1,075.5 Cr ₹822.8 Cr
Net Profit ₹11,509 Cr ₹10,965 Cr ₹9,610.03 Cr ₹8,512.94 Cr ₹3,389.28 Cr ₹4,171.96 Cr
  attributable to Owners ₹11,479 Cr ₹10,929 Cr ₹9,576.38 Cr ₹8,473.58 Cr ₹3,272.73 Cr ₹3,764.93 Cr
  attributable to NCI ₹29.23 Cr ₹35.71 Cr ₹33.65 Cr ₹39.36 Cr ₹116.55 Cr ₹407.03 Cr
Other Comprehensive Income ₹3,826.74 Cr ₹912.41 Cr ₹1,142.13 Cr ₹2,256.57 Cr ₹557.21 Cr ₹2,120.83 Cr
Total Comprehensive Income ₹15,335 Cr ₹11,877 Cr ₹10,752 Cr ₹10,770 Cr ₹3,946.49 Cr ₹6,292.79 Cr
EBITDA (computed) ₹19,703 Cr ₹17,237 Cr ₹14,377 Cr ₹12,281 Cr ₹11,319 Cr ₹7,625.74 Cr
Basic EPS ₹47.80 ₹45.60 ₹39.90 ₹35.30 ₹13.60 ₹15.69
Diluted EPS ₹47.80 ₹45.60 ₹39.90 ₹35.30 ₹13.60 ₹15.69
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹108,785 Cr ₹92,101 Cr ₹85,463 Cr ₹80,744 Cr
Non-current Assets ₹44,894 Cr ₹39,476 Cr ₹41,988 Cr ₹40,860 Cr
Current Assets ₹63,860 Cr ₹52,594 Cr ₹43,433 Cr ₹39,862 Cr
Property, Plant & Equipment ₹11,114 Cr ₹10,036 Cr ₹10,192 Cr ₹10,390 Cr
Inventories ₹11,493 Cr ₹10,243 Cr ₹9,868.29 Cr ₹10,513 Cr
Trade Receivables ₹15,510 Cr ₹13,046 Cr ₹11,249 Cr ₹11,439 Cr
Cash & Equivalents ₹9,770.51 Cr ₹10,269 Cr ₹9,285.65 Cr ₹4,623.73 Cr
Equity (Net Worth) ₹83,880 Cr ₹72,486 Cr ₹67,106 Cr ₹59,315 Cr
Equity Share Capital ₹239.93 Cr ₹239.93 Cr ₹239.93 Cr ₹239.93 Cr
Borrowings (Non-current) ₹31.26 Cr ₹2.52 Cr ₹1.33 Cr ₹0
Borrowings (Current) ₹4,050.35 Cr ₹1,867.11 Cr ₹2,844.36 Cr ₹6,197.88 Cr
Total Debt (computed) ₹4,081.61 Cr ₹1,869.63 Cr ₹2,845.69 Cr ₹6,197.88 Cr
Current Liabilities ₹22,622 Cr ₹18,194 Cr ₹16,984 Cr ₹19,906 Cr
Total Liabilities ₹24,905 Cr ₹19,615 Cr ₹18,357 Cr ₹21,428 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹12,419 Cr ₹14,072 Cr ₹12,135 Cr ₹4,959.33 Cr ₹8,984.54 Cr
Investing Cash Flow -₹11,344 Cr -₹5,306.16 Cr -₹690.2 Cr -₹7,943.68 Cr -₹5,724.74 Cr
Financing Cash Flow -₹2,512.55 Cr -₹7,905.82 Cr -₹6,710.16 Cr ₹2,376.07 Cr -₹5,193.46 Cr
Capital Expenditure ₹3,609.37 Cr ₹2,128.58 Cr ₹2,201.81 Cr ₹2,085.58 Cr ₹1,495.04 Cr
Free Cash Flow (computed) ₹8,809.81 Cr ₹11,944 Cr ₹9,933.17 Cr ₹2,873.75 Cr ₹7,489.5 Cr
Dividends Paid ₹3,937.8 Cr ₹3,617.3 Cr ₹2,900.71 Cr ₹2,519.73 Cr ₹2,169.19 Cr
Net Change in Cash -₹498.26 Cr ₹983.12 Cr ₹4,661.92 Cr ₹115.48 Cr -₹1,764.78 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹14,612 Cr ₹15,521 Cr ₹14,478 Cr ₹13,851 Cr ₹12,959 Cr ₹13,675 Cr ₹13,291 Cr ₹12,653 Cr ₹11,983 Cr ₹12,381 Cr ₹12,192 Cr ₹11,941 Cr
Other Income ₹458.5 Cr ₹578.84 Cr ₹469.92 Cr ₹464.46 Cr ₹612.87 Cr ₹465.62 Cr ₹354 Cr ₹532.55 Cr ₹605.94 Cr ₹250.2 Cr ₹293.61 Cr ₹204.44 Cr
Total Income ₹15,070 Cr ₹16,099 Cr ₹14,948 Cr ₹14,316 Cr ₹13,572 Cr ₹14,141 Cr ₹13,645 Cr ₹13,185 Cr ₹12,589 Cr ₹12,631 Cr ₹12,486 Cr ₹12,145 Cr
Cost of Materials Consumed ₹2,182.44 Cr ₹1,813.48 Cr ₹1,621.51 Cr ₹1,771.59 Cr ₹1,845.06 Cr ₹1,408.31 Cr ₹1,638.72 Cr ₹1,557.01 Cr ₹1,676.73 Cr ₹1,709.66 Cr ₹1,665.45 Cr ₹1,852.49 Cr
Purchases of Stock-in-Trade ₹753.34 Cr ₹922.42 Cr ₹1,087.79 Cr ₹1,047.98 Cr ₹1,036.73 Cr ₹1,238.69 Cr ₹875.1 Cr ₹997.43 Cr ₹982.88 Cr ₹796.49 Cr ₹1,006.82 Cr ₹679.96 Cr
Changes in Inventories -₹134.69 Cr ₹209.2 Cr ₹273.43 Cr -₹4.81 Cr -₹244.6 Cr ₹93.54 Cr ₹180.38 Cr ₹120.99 Cr -₹279.2 Cr ₹230.79 Cr ₹114.82 Cr ₹225.72 Cr
Employee Benefit Expense ₹2,960.41 Cr ₹2,892 Cr ₹2,764.79 Cr ₹2,801.66 Cr ₹2,488.52 Cr ₹2,552.28 Cr ₹2,477.7 Cr ₹2,454.62 Cr ₹2,299.34 Cr ₹2,363.32 Cr ₹2,364.36 Cr ₹2,402.04 Cr
Finance Costs ₹85.89 Cr ₹78.36 Cr ₹99.86 Cr ₹74.8 Cr ₹49.14 Cr ₹51.51 Cr ₹69.17 Cr ₹61.54 Cr ₹73.57 Cr ₹34.73 Cr ₹49.29 Cr ₹80.88 Cr
Depreciation & Amortisation ₹775.47 Cr ₹732.33 Cr ₹729.5 Cr ₹700.55 Cr ₹663.79 Cr ₹630.56 Cr ₹625.91 Cr ₹655.13 Cr ₹650.36 Cr ₹622.14 Cr ₹632.82 Cr ₹651.32 Cr
Other Expenses ₹4,896.09 Cr ₹4,734.95 Cr ₹4,203.74 Cr ₹3,933.32 Cr ₹4,117.04 Cr ₹4,373.62 Cr ₹4,180.53 Cr ₹3,915.08 Cr ₹4,268 Cr ₹3,803.61 Cr ₹3,861.58 Cr ₹3,448.86 Cr
Total Expenses ₹11,519 Cr ₹11,383 Cr ₹10,781 Cr ₹10,325 Cr ₹9,955.68 Cr ₹10,349 Cr ₹10,048 Cr ₹9,761.8 Cr ₹9,671.68 Cr ₹9,560.74 Cr ₹9,695.14 Cr ₹9,341.27 Cr
Profit Before Exceptional Items & Tax ₹3,551.34 Cr ₹4,716.64 Cr ₹4,167.61 Cr ₹3,990.77 Cr ₹3,616.03 Cr ₹3,792.57 Cr ₹3,597.88 Cr ₹3,423.5 Cr ₹2,917.16 Cr ₹3,070.16 Cr ₹2,790.88 Cr ₹2,804.01 Cr
Exceptional Items ₹0 -₹489.48 Cr ₹0 -₹818 Cr -₹361.68 Cr -₹316.17 Cr ₹0 ₹0 -₹101.64 Cr -₹69.81 Cr ₹0 -₹322.87 Cr
Profit Before Tax ₹3,551.34 Cr ₹4,227.16 Cr ₹4,167.61 Cr ₹3,172.77 Cr ₹3,254.35 Cr ₹3,476.4 Cr ₹3,597.88 Cr ₹3,423.5 Cr ₹2,815.52 Cr ₹3,000.35 Cr ₹2,790.88 Cr ₹2,481.14 Cr
Total Tax Expense ₹827.62 Cr ₹826.07 Cr ₹1,030.52 Cr ₹870.15 Cr ₹1,093.71 Cr ₹558.86 Cr ₹567.21 Cr ₹552.25 Cr ₹148.93 Cr ₹432.32 Cr ₹390.1 Cr ₹468.1 Cr
Net Profit ₹2,709.66 Cr ₹3,381.17 Cr ₹3,124.95 Cr ₹2,292.87 Cr ₹2,153.93 Cr ₹2,912.98 Cr ₹3,037.33 Cr ₹2,860.51 Cr ₹2,658.74 Cr ₹2,560.54 Cr ₹2,385.1 Cr ₹2,005.65 Cr
  attributable to Owners ₹2,714.03 Cr ₹3,368.81 Cr ₹3,117.95 Cr ₹2,278.63 Cr ₹2,149.88 Cr ₹2,903.38 Cr ₹3,040.16 Cr ₹2,835.62 Cr ₹2,654.58 Cr ₹2,523.75 Cr ₹2,375.51 Cr ₹2,022.54 Cr
  attributable to NCI -₹4.37 Cr ₹12.36 Cr ₹7 Cr ₹14.24 Cr ₹4.05 Cr ₹9.6 Cr -₹2.83 Cr ₹24.89 Cr ₹4.16 Cr ₹36.79 Cr ₹9.59 Cr -₹16.89 Cr
Other Comprehensive Income ₹1,503.37 Cr ₹780.52 Cr ₹1,415.43 Cr ₹127.42 Cr ₹335.33 Cr ₹117.94 Cr ₹417.75 Cr ₹41.39 Cr ₹281.27 Cr ₹424.94 Cr ₹219.25 Cr ₹216.67 Cr
Total Comprehensive Income ₹4,213.03 Cr ₹4,161.69 Cr ₹4,540.38 Cr ₹2,420.29 Cr ₹2,489.26 Cr ₹3,030.92 Cr ₹3,455.08 Cr ₹2,901.9 Cr ₹2,940.01 Cr ₹2,985.48 Cr ₹2,604.35 Cr ₹2,222.32 Cr
EBITDA (computed) ₹4,412.7 Cr ₹5,527.33 Cr ₹4,996.97 Cr ₹4,766.12 Cr ₹4,328.96 Cr ₹4,474.64 Cr ₹4,292.96 Cr ₹4,140.17 Cr ₹3,641.09 Cr ₹3,727.03 Cr ₹3,472.99 Cr ₹3,536.21 Cr
Basic EPS ₹11.30 ₹14.00 ₹13.00 ₹9.50 ₹9.00 ₹12.10 ₹12.70 ₹11.80 ₹11.10 ₹10.50 ₹9.90 ₹8.40
Diluted EPS ₹11.30 ₹14.00 ₹13.00 ₹9.50 ₹9.00 ₹12.10 ₹12.70 ₹11.80 ₹11.10 ₹10.50 ₹9.90 ₹8.40
Latest 12 quarters shown of 25 on record.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Revenue from Operations ₹20,755 Cr ₹23,003 Cr ₹20,275 Cr ₹20,812 Cr ₹15,586 Cr ₹12,803 Cr ₹12,532 Cr
Other Income ₹419.33 Cr ₹369.43 Cr ₹465.76 Cr ₹279.03 Cr ₹957.92 Cr ₹150.22 Cr ₹1,510.92 Cr
Total Income ₹21,174 Cr ₹23,373 Cr ₹20,741 Cr ₹21,091 Cr ₹16,544 Cr ₹12,953 Cr ₹14,043 Cr
Cost of Materials Consumed ₹4,383.27 Cr ₹4,690.67 Cr ₹4,429.38 Cr ₹5,165.63 Cr ₹4,584.97 Cr ₹3,809.11 Cr ₹3,201.71 Cr
Purchases of Stock-in-Trade ₹1,391.52 Cr ₹1,359.53 Cr ₹994.41 Cr ₹1,126.46 Cr ₹1,248.6 Cr ₹1,199.63 Cr ₹1,227.41 Cr
Changes in Inventories -₹305.83 Cr -₹69.17 Cr ₹180.32 Cr -₹237.93 Cr -₹183.18 Cr -₹214.84 Cr ₹138.6 Cr
Employee Benefit Expense ₹2,911.3 Cr ₹2,608.26 Cr ₹2,373.95 Cr ₹2,156.95 Cr ₹2,000.78 Cr ₹1,798.45 Cr ₹1,702.77 Cr
Finance Costs ₹947.84 Cr ₹893.21 Cr ₹784.08 Cr ₹472.18 Cr ₹388.1 Cr ₹256.98 Cr ₹408.01 Cr
Depreciation & Amortisation ₹1,311.72 Cr ₹1,238.27 Cr ₹1,600.62 Cr ₹1,600.87 Cr ₹1,349.95 Cr ₹586.81 Cr ₹561.56 Cr
Other Expenses ₹6,193.69 Cr ₹7,621.42 Cr ₹6,709.5 Cr ₹6,128.17 Cr ₹5,027.29 Cr ₹3,274.86 Cr ₹3,549.79 Cr
Total Expenses ₹16,834 Cr ₹18,342 Cr ₹17,072 Cr ₹16,412 Cr ₹14,417 Cr ₹10,711 Cr ₹10,790 Cr
Profit Before Exceptional Items & Tax ₹4,340.46 Cr ₹5,030.57 Cr ₹3,668.67 Cr ₹4,678.84 Cr ₹2,127.39 Cr ₹2,242.43 Cr ₹3,253 Cr
Exceptional Items -₹546.34 Cr ₹0 -₹219.02 Cr -₹2,937.79 Cr -₹1,820.53 Cr -₹89.56 Cr ₹0
Profit Before Tax ₹3,794.12 Cr ₹5,030.57 Cr ₹3,449.65 Cr ₹1,741.05 Cr ₹306.86 Cr ₹2,152.87 Cr ₹3,253 Cr
Total Tax Expense ₹1,170.7 Cr ₹747.95 Cr ₹591.47 Cr ₹50.33 Cr ₹406.85 Cr ₹13.17 Cr ₹41.86 Cr
Net Profit ₹2,623.42 Cr ₹4,282.62 Cr ₹2,858.18 Cr ₹1,690.72 Cr -₹99.99 Cr ₹2,139.7 Cr ₹3,211.14 Cr
Other Comprehensive Income -₹219.05 Cr -₹23.2 Cr -₹13.98 Cr -₹11.01 Cr -₹91.62 Cr ₹63.3 Cr -₹80.8 Cr
Total Comprehensive Income ₹2,404.37 Cr ₹4,259.42 Cr ₹2,844.2 Cr ₹1,679.71 Cr -₹191.61 Cr ₹2,203 Cr ₹3,130.34 Cr
EBITDA (computed) ₹6,600.02 Cr ₹7,162.05 Cr ₹6,053.37 Cr ₹6,751.89 Cr ₹3,865.44 Cr ₹3,086.22 Cr ₹4,222.57 Cr
Basic EPS ₹10.90 ₹17.80 ₹11.90 ₹7.00 ₹-0.40 ₹8.92 ₹13.38
Diluted EPS ₹10.90 ₹17.80 ₹11.90 ₹7.00 ₹-0.40 ₹8.92 ₹13.38
Metrics FY 2026 FY 2025 FY 2024 FY 2023
Total Assets ₹43,060 Cr ₹43,273 Cr ₹41,065 Cr ₹40,987 Cr
Non-current Assets ₹26,350 Cr ₹24,521 Cr ₹26,110 Cr ₹24,522 Cr
Current Assets ₹16,679 Cr ₹18,722 Cr ₹14,913 Cr ₹16,444 Cr
Property, Plant & Equipment ₹5,145.4 Cr ₹4,345.05 Cr ₹4,539.14 Cr ₹4,733.25 Cr
Inventories ₹4,302.27 Cr ₹3,787.49 Cr ₹3,423.62 Cr ₹3,989.19 Cr
Trade Receivables ₹10,166 Cr ₹11,701 Cr ₹8,834.16 Cr ₹7,125.02 Cr
Cash & Equivalents ₹417.84 Cr ₹492.02 Cr ₹326.46 Cr ₹410.28 Cr
Equity (Net Worth) ₹22,371 Cr ₹24,340 Cr ₹23,694 Cr ₹23,748 Cr
Equity Share Capital ₹239.93 Cr ₹239.93 Cr ₹239.93 Cr ₹239.93 Cr
Borrowings (Non-current) ₹13,420 Cr ₹0 ₹11,036 Cr ₹7,586.73 Cr
Borrowings (Current) ₹0 ₹10,954 Cr ₹10.6 Cr ₹5.94 Cr
Total Debt (computed) ₹13,420 Cr ₹10,954 Cr ₹11,047 Cr ₹7,592.67 Cr
Current Liabilities ₹6,503.24 Cr ₹18,149 Cr ₹4,444.51 Cr ₹8,365.44 Cr
Total Liabilities ₹20,689 Cr ₹18,934 Cr ₹17,370 Cr ₹17,239 Cr
The balance sheet became part of the exchange results-filing format in FY2023 - earlier years were not filed and are hidden.
Metrics FY 2026 FY 2025 FY 2024 FY 2023 FY 2022
Operating Cash Flow ₹6,500.87 Cr ₹4,198.77 Cr -₹292.42 Cr ₹507.08 Cr ₹7,636.36 Cr
Investing Cash Flow -₹1,380.95 Cr -₹209.56 Cr -₹262.91 Cr -₹705.17 Cr -₹2,702.1 Cr
Financing Cash Flow -₹5,230.18 Cr -₹3,831.18 Cr ₹473.95 Cr ₹169.31 Cr -₹4,870.85 Cr
Capital Expenditure ₹1,542.78 Cr ₹710.51 Cr ₹749.24 Cr ₹962.43 Cr ₹849.9 Cr
Free Cash Flow (computed) ₹4,958.09 Cr ₹3,488.26 Cr -₹1,041.66 Cr -₹455.35 Cr ₹6,786.46 Cr
Dividends Paid ₹3,933.9 Cr ₹3,613.97 Cr ₹2,898.17 Cr ₹2,518.88 Cr ₹2,158.92 Cr
Net Change in Cash -₹74.73 Cr ₹165.56 Cr -₹83.82 Cr -₹9.25 Cr ₹68.47 Cr
The cash-flow statement became part of the exchange results-filing format in FY2022 - earlier years were not filed and are hidden.
Metrics Q4 FY26 Q3 FY26 Q2 FY26 Q1 FY26 Q4 FY25 Q3 FY25 Q2 FY25 Q1 FY25 Q4 FY24 Q3 FY24 Q2 FY24 Q1 FY24
Revenue from Operations ₹4,923.88 Cr ₹5,687.77 Cr ₹4,548.11 Cr ₹5,601.96 Cr ₹7,185.74 Cr ₹6,191.81 Cr ₹5,127.71 Cr ₹4,498.07 Cr ₹5,639.14 Cr ₹5,073.75 Cr ₹5,096.21 Cr ₹4,466.07 Cr
Other Income ₹62.93 Cr ₹179.9 Cr ₹72.79 Cr ₹103.69 Cr ₹132 Cr ₹68.39 Cr ₹86.3 Cr ₹82.74 Cr ₹118.88 Cr ₹76.8 Cr ₹106.54 Cr ₹163.54 Cr
Total Income ₹4,986.81 Cr ₹5,867.67 Cr ₹4,620.9 Cr ₹5,705.65 Cr ₹7,317.74 Cr ₹6,260.2 Cr ₹5,214.01 Cr ₹4,580.81 Cr ₹5,758.02 Cr ₹5,150.55 Cr ₹5,202.75 Cr ₹4,629.61 Cr
Cost of Materials Consumed ₹1,228.66 Cr ₹1,160.49 Cr ₹996.19 Cr ₹1,067.24 Cr ₹1,329.7 Cr ₹1,162.73 Cr ₹1,225.01 Cr ₹973.23 Cr ₹1,055.87 Cr ₹1,121.64 Cr ₹1,066.9 Cr ₹1,184.97 Cr
Purchases of Stock-in-Trade ₹311.91 Cr ₹413.27 Cr ₹338.09 Cr ₹328.25 Cr ₹325.7 Cr ₹367.48 Cr ₹360.09 Cr ₹306.26 Cr ₹289.5 Cr ₹227.2 Cr ₹264.65 Cr ₹213.06 Cr
Changes in Inventories -₹345.37 Cr -₹68.96 Cr ₹15.48 Cr ₹95.92 Cr -₹2.07 Cr ₹131.29 Cr -₹142.86 Cr -₹55.53 Cr -₹29.97 Cr ₹129.13 Cr ₹52.7 Cr ₹28.46 Cr
Employee Benefit Expense ₹703.99 Cr ₹739.62 Cr ₹728.77 Cr ₹715 Cr ₹648.91 Cr ₹651.68 Cr ₹662.19 Cr ₹645.48 Cr ₹575.97 Cr ₹590.13 Cr ₹600.41 Cr ₹607.44 Cr
Finance Costs ₹216.92 Cr ₹244.17 Cr ₹248.33 Cr ₹223.29 Cr ₹217.42 Cr ₹215.96 Cr ₹243.75 Cr ₹216.08 Cr ₹217.59 Cr ₹214.92 Cr ₹193.63 Cr ₹157.94 Cr
Depreciation & Amortisation ₹325.97 Cr ₹338.53 Cr ₹336.3 Cr ₹299.03 Cr ₹291.96 Cr ₹290.97 Cr ₹285.53 Cr ₹369.81 Cr ₹393.04 Cr ₹399.6 Cr ₹392.71 Cr ₹415.27 Cr
Other Expenses ₹1,695.72 Cr ₹1,684.75 Cr ₹1,285.99 Cr ₹1,504.4 Cr ₹1,894.04 Cr ₹2,175.16 Cr ₹1,684.66 Cr ₹1,867.56 Cr ₹1,854.24 Cr ₹1,646.65 Cr ₹1,725.23 Cr ₹1,483.38 Cr
Total Expenses ₹4,137.8 Cr ₹4,511.87 Cr ₹3,949.15 Cr ₹4,233.13 Cr ₹4,705.66 Cr ₹4,995.27 Cr ₹4,318.37 Cr ₹4,322.89 Cr ₹4,356.24 Cr ₹4,329.27 Cr ₹4,296.23 Cr ₹4,090.52 Cr
Profit Before Exceptional Items & Tax ₹849.01 Cr ₹1,355.8 Cr ₹671.75 Cr ₹1,472.52 Cr ₹2,612.08 Cr ₹1,264.93 Cr ₹895.64 Cr ₹257.92 Cr ₹1,401.78 Cr ₹821.28 Cr ₹906.52 Cr ₹539.09 Cr
Exceptional Items ₹0 -₹258.7 Cr ₹0 -₹287.64 Cr ₹0 ₹0 ₹0 ₹0 ₹0 -₹69.81 Cr ₹0 -₹149.21 Cr
Profit Before Tax ₹849.01 Cr ₹1,097.1 Cr ₹671.75 Cr ₹1,184.88 Cr ₹2,612.08 Cr ₹1,264.93 Cr ₹895.64 Cr ₹257.92 Cr ₹1,401.78 Cr ₹751.47 Cr ₹906.52 Cr ₹389.88 Cr
Total Tax Expense ₹240.31 Cr ₹391.66 Cr ₹107.53 Cr ₹431.35 Cr ₹611.62 Cr ₹83.88 Cr ₹32.35 Cr ₹20.1 Cr ₹534.18 Cr ₹30.16 Cr ₹17.89 Cr ₹9.24 Cr
Net Profit ₹608.7 Cr ₹705.44 Cr ₹564.22 Cr ₹753.53 Cr ₹2,000.46 Cr ₹1,181.05 Cr ₹863.29 Cr ₹237.82 Cr ₹867.6 Cr ₹721.31 Cr ₹888.63 Cr ₹380.64 Cr
Other Comprehensive Income -₹142.69 Cr ₹57 Lakh -₹96.61 Cr ₹19.27 Cr ₹27.06 Cr -₹47.44 Cr -₹19.4 Cr ₹16.58 Cr -₹9.96 Cr ₹6.26 Cr -₹33.62 Cr ₹23.33 Cr
Total Comprehensive Income ₹466.01 Cr ₹706.01 Cr ₹467.61 Cr ₹772.8 Cr ₹2,027.52 Cr ₹1,133.61 Cr ₹843.89 Cr ₹254.4 Cr ₹857.64 Cr ₹727.57 Cr ₹855.01 Cr ₹403.97 Cr
EBITDA (computed) ₹1,391.9 Cr ₹1,938.5 Cr ₹1,256.38 Cr ₹1,994.84 Cr ₹3,121.46 Cr ₹1,771.86 Cr ₹1,424.92 Cr ₹843.81 Cr ₹2,012.41 Cr ₹1,435.8 Cr ₹1,492.86 Cr ₹1,112.3 Cr
Basic EPS ₹2.50 ₹2.90 ₹2.40 ₹3.10 ₹8.30 ₹4.90 ₹3.60 ₹1.00 ₹3.60 ₹3.00 ₹3.70 ₹1.60
Diluted EPS ₹2.50 ₹2.90 ₹2.40 ₹3.10 ₹8.30 ₹4.90 ₹3.60 ₹1.00 ₹3.60 ₹3.00 ₹3.70 ₹1.60
Latest 12 quarters shown of 24 on record.
Want more history and ratios?
You're viewing the latest exchange-filed financials for Sun Pharmaceutical Industries Limited. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Shareholding Pattern of Sun Pharmaceutical Industries Limited

As per the shareholding pattern filed with NSE for the quarter ended Mar 2026, promoters hold 54.48%, foreign institutional investors hold 15.93%, domestic institutional investors hold 21.11%, retail and other public shareholders hold 8.48% of Sun Pharmaceutical Industries Limited. The company had 690,957 shareholders on record.

Promoters: 54.48%DII (Domestic Institutional): 21.11%FII (Foreign Institutional): 15.93%Retail & Others: 8.48%
Mar 2026
QUARTER
54.48% Promoters
21.11% DII (Domestic Institutional)
15.93% FII (Foreign Institutional)
8.48% Retail & Others
Promoter holding - history
Now 54.48% · Mar 2026High 54.97% · Dec 2015Low 54.38% · Jun 2017
53%53.8%54.5%55.3%56%Dec 2015Jun 2018Dec 2020Jun 2023Dec 2025Dec 2015: 54.97%Mar 2016: 54.97%Jun 2016: 54.97%Sep 2016: 54.97%Dec 2016: 54.39%Mar 2017: 54.39%Jun 2017: 54.38%Sep 2017: 54.38%Dec 2017: 54.38%Mar 2018: 54.38%Jun 2018: 54.38%Sep 2018: 54.38%Dec 2018: 54.38%Mar 2019: 54.38%Jun 2019: 54.38%Sep 2019: 54.55%Dec 2019: 54.56%Mar 2020: 54.69%Jun 2020: 54.69%Sep 2020: 54.69%Dec 2020: 54.48%Mar 2021: 54.48%Jun 2021: 54.48%Sep 2021: 54.48%Dec 2021: 54.48%Mar 2022: 54.48%Jun 2022: 54.48%Sep 2022: 54.48%Dec 2022: 54.48%Mar 2023: 54.48%Jun 2023: 54.48%Sep 2023: 54.48%Dec 2023: 54.48%Mar 2024: 54.48%Jun 2024: 54.48%Sep 2024: 54.48%Dec 2024: 54.48%Mar 2025: 54.48%Jun 2025: 54.48%Sep 2025: 54.48%Dec 2025: 54.48%Mar 2026: 54.48%54.97%54.38%54.48%
Shareholding trend - last 6 quarters
Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Promoters54.48%54.48%54.48%54.48%54.48%54.48%
Public45.52%45.52%45.52%45.52%45.52%45.52%
Shareholding history - year on year (as at 31 March)
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016
Promoters54.48%54.48%54.48%54.48%54.48%54.48%54.69%54.38%54.38%54.39%54.97%
Public45.52%45.52%45.52%45.52%45.52%45.52%45.31%45.62%45.62%45.61%45.02%
Employee Trusts0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.01%
Promoter change (YoY, %pts)+0.00+0.00+0.00+0.00+0.00-0.21+0.31+0.00-0.01-0.58-

Board & Governance of Sun Pharmaceutical Industries Limited

As per the corporate governance filing with NSE for the quarter ended 31-MAR-2026, the board of Sun Pharmaceutical Industries Limited has 8 directors - 4 independent and 4 executive. The board is chaired by Dilip Shantilal Shanghvi.

DirectorPositionOn board sinceListed boards
Dilip Shantilal Shanghvi Executive Director · Chairperson 1993-03-01 2
Kirti Wardhaman Ganorkar Executive Director · MD 2025-09-01 1
Pawan Kumar Goenka Non-Executive - Independent Director 2021-05-21 2
Gautam Bhailal Doshi Non-Executive - Independent Director 2018-05-25 2
Rama Bijapurkar Non-Executive - Independent Director 2021-05-21 4
Rolf Hoffmann Non-Executive - Independent Director 2023-06-15 1
Aalok Dilip Shanghvi Executive Director 2023-06-01 1
Vidhi Dilip Shanghvi Executive Director 2025-05-22 2
Board Committees
CommitteeMembers
Audit Committee Gautam Bhailal Doshi (Chairperson), Pawan Kumar Goenka, Rama Bijapurkar
Nomination and remuneration committee Pawan Kumar Goenka (Chairperson), Gautam Bhailal Doshi, Rolf Hoffmann, Dilip Shantilal Shanghvi
Stakeholders Relationship Committee Gautam Bhailal Doshi (Chairperson), Pawan Kumar Goenka, Aalok Dilip Shanghvi, Kirti Wardhaman Ganorkar
Risk Management Committee Pawan Kumar Goenka (Chairperson), Gautam Bhailal Doshi, Dilip Shantilal Shanghvi, Aalok Dilip Shanghvi, Jayashree Satagopan
Corporate Social Responsibility Committee Rama Bijapurkar (Chairperson), Pawan Kumar Goenka, Dilip Shantilal Shanghvi, Vidhi Dilip Shanghvi
Corporate Governance and ESG Committee Gautam Bhailal Doshi (Chairperson), Pawan Kumar Goenka, Kirti Wardhaman Ganorkar, Jayashree Satagopan, Anoop Deshpande

Group Structure of Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has 14 subsidiary companies and 1 associated company. This group structure data is as of FY 2024. The corporate group structure reflects Sun Pharmaceutical Industries Limited's business expansion strategy and organizational complexity.

14
Subsidiary companies
1
Associated companies
Key Subsidiaries
Company Name CIN Shares Held
Zenotech Laboratories Limited L27100TG1989PLC010122 -
Caraco Pharmaceuticals Private Limited U24100MH2012FTC225970 -
Vivaldis Health And Foods Private Limited U24297PN2014PTC150393 -
Sun Pharma Laboratories Limited U25200GJ1997PLC133846 -
Sun Pharmaceutical Medicare Limited U36900GJ2017PLC095132 -
Neetnav Real Estate Private Limited U45200MH2010PTC201611 -

Showing major subsidiaries. Total: 14.

Charges & Borrowings of Sun Pharmaceutical Industries Limited

Open charges
₹16.06 Cr
Satisfied charges
₹1,785.22 Cr
Breakdown by lending institutions
Industrial Development Bank of India₹12.45 Cr
Risk Capital and Technology Finance Corporation Ltd₹1.50 Cr
Gujarat Industrial Investment Corporation Ltd.₹1.36 Cr
Nvfc Finance Private Ltd₹0.75 Cr
Latest charge details
DateLenderAmountStatus
26 May 1999 Nvfc Finance Private Ltd ₹75 Lakh Open
29 Apr 1999 Risk Capital and Technology Finance Corporation Ltd ₹1.5 Cr Open
17 Nov 1998 Industrial Development Bank of India ₹3.25 Cr Open
13 Sep 1996 Industrial Development Bank of India ₹9.2 Cr Open
11 Oct 1993 Gujarat Industrial Investment Corporation Ltd. ₹1.36 Cr Open

Total charge records: 38 View all charges

Employees and EPFO Compliance at Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited has a workforce of 16,436 employees as of Oct 28, 2024.

Employee count
16,436
Active EPFO establishments
7
Employee growth
-15.94%
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026

Employee Count & EPFO Data of Sun Pharmaceutical Industries Limited

Access employee headcount trends, monthly PF payment records, EPFO establishment details, and compliance data.

Monthly employee headcount & PF contributions
EPFO establishment details & ECR filing status
Year-wise workforce analytics & attrition trends
PF exemption, coverage & compliance verification

GST Compliance of Sun Pharmaceutical Industries Limited

XX%
Compliant
GSTR-1
GSTR-3B
GSTR-9
MH
KA
UP
TN
TS

GSTIN & GST Filing Data of Sun Pharmaceutical Industries Limited

Access GSTIN registrations, state-wise filing compliance, HSN/SAC codes, and detailed goods & services data.

GSTIN registrations & state-wise presence
Filing compliance - GSTR-1, GSTR-3B, GSTR-9
HSN/SAC codes with goods & services details
Taxpayer type, jurisdiction & business constitution

Credit Ratings, Litigation & Regulatory Alerts for Sun Pharmaceutical Industries Limited

Credit rating
AAA
AA+
AA
AA-
! !
2015 2017 2019 2021 2023
Litigation
District Court 35
High Court 45
Supreme Court 0
NCLT / NCLAT 0
Pending
Disposed
Regulatory alerts
GSTIN Cancelled
Andhra Pradesh
GSTIN Cancelled
Telangana (on application)
EPFO Delay
12 months delay - Haryana
Violations via Directors
20 MCA + 19 Bank defaults

Credit Ratings, Legal Cases & Regulatory Alerts of Sun Pharmaceutical Industries Limited

Access complete credit rating history, litigation records, regulatory alerts, and compliance data.

Credit rating history across CARE, ICRA, Brickwork & India Ratings
Instrument-wise ratings, outlook & action timeline
Court-wise litigation (District, High Court, Supreme Court, NCLT)
Group company & common directorship litigation
Statutory compliance alerts (GSTIN, EPFO, ROC)
Director & company violations (MCA, SEBI, Banks, BSE/NSE)

MSME Payment Delays by Sun Pharmaceutical Industries Limited

MSME Payment Delays by Sun Pharmaceutical Industries Limited

Track payments outstanding to micro and small enterprise vendors, as disclosed in half-yearly MSME-1 returns filed with the MCA.

Amounts outstanding to MSME suppliers
Delay periods & reasons for delayed payments
Half-yearly MSME-1 filing history
Vendor-payment behaviour as a counterparty risk signal

Subsidiaries & Group Companies of Sun Pharmaceutical Industries Limited

Subsidiaries & Group Companies of Sun Pharmaceutical Industries Limited

See the full corporate group - holding company, subsidiaries, associates and joint ventures of Sun Pharmaceutical Industries Limited with ownership details.

Holding & parent company details
Subsidiaries & step-down subsidiaries with % holding
Associates & joint ventures with partner details
Investments in other entities year-on-year

MCA Filings & Documents of Sun Pharmaceutical Industries Limited

MCA Filings & Documents of Sun Pharmaceutical Industries Limited

Download official documents filed with the Ministry of Corporate Affairs - from incorporation papers to the latest annual filings.

Incorporation documents, MoA & AoA
Annual returns (MGT-7) & financial statements (AOC-4)
Charge filings (CHG-1, CHG-4) & resolutions
Complete document index with filing dates

Recent Activity on Sun Pharmaceutical Industries Limited

Directors
01 Sep 2025
Kirti Wardhaman Ganorkar was appointed as a Managing Director on 01 Sep 2025 & has been associated with this company since 10 months 8 days.
Activity
31 Jul 2025
Sun Pharmaceutical Industries Limited last Annual general meeting of members was held on 31 Jul 2025 as per latest MCA records.
Directors
01 Jul 2025
Jayashree Satagopan was appointed as a CFO on 01 Jul 2025 & has been associated with this company since 1 year 9 days.
Directors
22 May 2025
Vidhi Dilip Shanghvi was appointed as a Whole-time director on 22 May 2025 & has been associated with this company since 1 year 1 month.
Activity
31 Mar 2025
Sun Pharmaceutical Industries Limited has filed its annual Financial statements for the year ended 31 Mar 2025 with Roc Ahmedabad.
Directors
15 Jun 2023
Rolf Karl Heinz Hoffmann was appointed as a Director on 15 Jun 2023 & has been associated with this company since 3 years 26 days.

Recent News on Sun Pharmaceutical Industries Limited

Frequently Asked Questions about Sun Pharmaceutical Industries Limited

Sun Pharmaceutical Industries Limited is an active public limited company in the pharma sector based in Vadodara, Gujarat, India. It was incorporated on 01 March 1993 (33+ years old) and is registered under CIN L24230GJ1993PLC019050. Listed on BSE: 524715 and NSE: SUNPHARMA. The company has 16,436 employees.

Sun Pharmaceutical Industries Limited reported revenue of ₹54,543 Cr for FY 2025 (up 9.00% YoY).

The current directors of Sun Pharmaceutical Industries Limited are:

The primary industry of Sun Pharmaceutical Industries Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.

Yes. Sun Pharmaceutical Industries Limited is listed on both BSE (code: 524715) and NSE (symbol: SUNPHARMA).

Sun Pharmaceutical Industries Limited can be reached at the registered office: Sparc Tandalja, Vadodara, Gujarat, India – 390012, or through the website sunpharma.com.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - sourced from MCA, SEBI and RBI filings.

Subscription plans available